A Phase 1/2 Open-Label, Multicenter, Global Trial to Characterize the Safety, Tolerability and Preliminary Efficacy of CFT1946 as a Monotherapy and in Combination with Trametinib in Subjects with BRAF

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Aparna Nallagangula
Sponsor
C4 Therapeutics, Inc.
Unit
Cancer Center Division